Clinical trials: Breast Cancer Risk
Breast Carcinoma
Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer.
- Trial name
- NCT07216274
- Testing
- QT Ultrasound Breast Scanner, Questionnaire Administration
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
Green Tea and Reduction of Breast Cancer Risk
RATIONALE: Green tea extract contains ingredients (catechins) that may lower the risk of breast cancer. PURPOSE: This phase II trial is studying how well green tea extract works in preventing breast cancer compared to a placebo…
- Trial name
- NCT00917735
- Testing
- Green tea extract supplement
- Where
- 5 sites in United States
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Breast Cancer
Breast Cancer Risk Biomarkers in Postmenopausal Women
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer.
- Trial name
- NCT01252290
- Testing
- Lovaza™
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer…
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Trial name
- NCT04674306
- Testing
- α-lactalbumin vaccine, Zymosan
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- George T. Budd
Breast Cancer
Dietary Fat, Eicosanoids and Breast Cancer Risk
The primary objective of this investigation is to determine whether diets designed to increase plasma n3 concentrations (a low fat diet, with or without n3 fatty acid enrichment), will favorably affect sex hormone distribution in…
- Trial name
- NCT01824498
- Testing
- Low Fat diet, Low Fat high n3 diet, High Fat Diet
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- USDA Grand Forks Human Nutrition Research Center
Breast Cancer
Soy Protein and Breast Cancer Risk Reduction
Soy consumption has been associated with reduced risk for developing breast cancer. Ovarian hormones and breast density are considered breast cancer risk markers.
- Trial name
- NCT00204477
- Testing
- soy milk, cow's milk
- Where
- United States
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Ductal Carcinoma in Situ
Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)
The purpose of this research study is to evaluate a decision support tool for patients diagnosed with ductal carcinoma in situ (DCIS).
- Trial name
- NCT03775213
- Testing
- Decision Support Tool with Active Monitoring, Decision Support Tool without Active Monitoring
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- Duke University
Breast Cancer
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
This phase II trial is studying how well acolbifene works in preventing cancer in premenopausal women at high risk of breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming.
- Trial name
- NCT00853996
- Testing
- acolbifene hydrochloride
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Breast Cancer Survivor, Breast Cancer
Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)
The purpose of this study is to develop and test a mobile app for Black/African American breast cancer survivors and their relatives, called Move Together, that promotes sitting less and moving more for better health.
- Conditions
- Breast Cancer Survivor, Breast Cancer, Fitness Trackers
- Trial name
- NCT05011279
- Testing
- Move Together app/Garmin Activity Tracker
- Where
- 3 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer
This proposal is for a pilot study of 20 premenopausal women at high risk for breast cancer development who will receive high dose vitamin D3, cholecalciferol 20,000 IU (2 capsules) weekly, or 30,000 IU (3 capsules) weekly, for 1…
- Trial name
- NCT00976339
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Katherine D. Crew
Breast Cancer
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen.
- Trial name
- ExCel (NCT00083174)
- Testing
- exemestane
- Where
- 76 sites in United States, Canada and 2 more
- Volunteers
- 4,560 people, healthy volunteers welcome
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
A new test for breast cancer screening, molecular breast imaging (MBI) may be more sensitive than mammography for detecting breast cancer in women with dense breasts.
- Trial name
- NCT01925170
- Testing
- Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
- Where
- United States
- Volunteers
- 1,638 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
The central goal of this study is to test strategies to implement evidence-based breast cancer risk assessment in healthcare clinics in Tennessee.
- Trial name
- BRAVE (NCT05051631)
- Testing
- Intervention plus 12 months maintenance, Intervention plus 10 months maintenance, Intervention plus 8 months maintenance
- Where
- United States
- Volunteers
- 1,071 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Breast Cancer
Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer
RATIONALE: Screening tests may help doctors find cancer cells early and plan better treatment for breast cancer. It is not yet known whether positron emission mammography is more effective than standard mammography in finding…
- Trial name
- NCT00896649
- Testing
- questionnaire administration, digital mammography, positron emission mammography
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Breast Neoplasms
Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates
This multicenter trial using Hologic digital mammography units will evaluate the specificity of 2-D full field digital mammography (FFDM) versus a combination of 2-D and 3-D tomosynthesis imaging in breast cancer screening.
- Trial name
- NCT01236781
- Testing
- Screening Tomosynthesis, Diagnostic Tomosynthesis
- Where
- 2 sites in United States
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- American College of Radiology
Women's Health: Neoplasm of Breast
Breast Cancer: Feasibility of an Educational Intervention
Aim: To evaluate the viability of an educational intervention for the prevention of breast cancer risk and the modification of their risk behaviors through the use of a web application in women living in the Principality of…
- Trial name
- PRECAM-2 (NCT04396665)
- Testing
- Precam
- Where
- Spain
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- University of Oviedo
Breast Neoplasm, Primary Prevention
Project Breast47: Effect of an Educational Intervention
Breast cancer is the most frequently diagnosed malignant tumor in women. In 2018, in Spain, the estimated incidence was 101/100,000 women.
- Conditions
- Breast Neoplasm, Primary Prevention, Risk Factors, Telemedicine
- Trial name
- Breast47 (NCT05267171)
- Testing
- Web access
- Where
- Spain
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- University of Oviedo
Breast Cancer, Ovarian Cancer
Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project
GRACE is a randomized 3-arm trial to determine the comparative effectiveness of two remote cancer communication interventions: 1) a targeted generic print (TP) or 2) a tailored telephone-based counseling and navigation…
- Trial name
- GRACE (NCT03326713)
- Testing
- Telephone Counseling & Navigation (TCN), Mailed Targeted Print (TP), Usual Care (UC)
- Where
- United States
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.
- Trial name
- NCT01276704
- Testing
- secoisolariciresinol
- Where
- 7 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Risk Reduction, Mammographic Density Reduction
Low Dose Tamoxifen for Mammographic Density Reduction
KARISMA2 is a randomized, double-blinded, six-armed placebo controlled study to identify a low dose of tamoxifen, with less side-effects and a density reduction non-inferior to the standard dose of 20 mg.
- Trial name
- KARISMA2 (NCT03346200)
- Testing
- Tamoxifen Oral Tablet
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- Per Hall